Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Placebo-Controlled Phase 3 Study of Dapoxetine for Premature Ejaculation
2004-002700-16Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dapoxetine in premature ejaculation (PE) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Average intravaginal ejaculatory latency time at end of treatment. Started Oct 2004; status: completed.
02
Drugs
dapoxetine
03
Conditions
premature ejaculation (PE)
Beyond the preview
Go deeper on 2004-002700-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-002700-16.